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Abstract
Medication nonadherence is a significant health care issue requiring regular behavioral treatment. 
Lack of sufficient health care resources and patient/family time commitment for weekly treatment 
are primary barriers to receiving appropriate self-management support. We describe the 
methodology of the Telehealth Enhancement of Adherence to Medication (TEAM) trial for 
Address correspondence to: Kevin A. Hommel, Ph.D., Center for Adherence and Self-Management; Division of Behavioral Medicine 
and Clinical Psychology; Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue MLC-7039, Cincinnati, OH 45229; 
(513) 803-0407; fax (513) 803-0415; kevin.hommel@cchmc.org. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Contemp Clin Trials. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:













medication nonadherence in pediatric inflammatory bowel disease (IBD). For this trial, 
participants 11–18 years of age will be recruited from seven pediatric hospitals and will complete 
an initial 4-week run in to assess adherence to a daily medication. Those who take less than 90% 
of their prescribed medication will be randomized. A total of 194 patients with IBD will be 
randomized to either a telehealth behavioral treatment (TBT) arm or education only (EO) arm. All 
treatment will be delivered via telehealth video conferencing. Patients will be assessed at baseline, 
post-treatment, 3-, 6-, and 12-months. We anticipate that participants in the TBT arm will 
demonstrate a statistically significant improvement at post-treatment and 3-, 6-, and 12-month 
follow-up compared to participants in the EO arm for both medication adherence and secondary 
outcomes (i.e., disease severity, patient quality of life, and health care utilization). If efficacious, 
the TEAM intervention could be disseminated broadly and reduce health care access barriers so 
that patients could receive much needed self-management intervention.
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1. Introduction
Nonadherence to medication is a critical clinical care issue with an estimated cost of $100–
300 billion annually1,2. Across chronic illness populations, nonadherence is associated with 
increased disease morbidity3–8, poorer quality of life and psychological functioning9–11, 
higher risk of mortality12–14, and greater health care utilization15,16. Published reports 
indicate that as many as 50% of children6, and 65–88% of adolescents17,18, are nonadherent 
to treatment, increasing the risk of complications substantially.
Although nonadherence to medical treatment is common across all pediatric chronic 
conditions, adolescents with Crohn’s disease, ulcerative colitis, and indeterminate colitis, 
collectively known as Inflammatory Bowel Disease (IBD), are among the highest at risk for 
nonadherence, with nonadherence prevalence rates reported as high as 88%18. IBD is 
characterized by gastrointestinal inflammation leading to unpredictable periods of disease 
exacerbation (e.g., abdominal pain, diarrhea, bloody stools, delayed growth) and 
remission19, and affects approximately 71 of 100,000 individuals20 (mean age of diagnosis 
in pediatrics = 15 years)21. Treatment may involve multiple oral medications (e.g., 
mesalamine, immunomodulators, corticosteroids)22, often with varying dosing schedules 
and undesirable side effects (e.g., facial hair growth, emotional symptoms, acne, weight 
gain).
Reasons for nonadherence in adolescents with IBD are largely behavioral and include 
forgetting, being too busy, interference of the medication with an activity, and being away 
from home4,23–25. Multicomponent behavioral interventions have demonstrated efficacy at 
improving adherence in the IBD population26–29, with one study reporting a 25% 
improvement in mesalamine adherence27. Despite preliminary efficacy of such 
interventions, many who would benefit from treatment do not receive it due to time and 
distance barriers. At our clinic, the average IBD patient must travel over 20 miles/30 
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minutes each way to receive care. Most behavioral interventions necessitate 1 to 2 hour-long 
sessions on a weekly/bimonthly basis, representing a significant time investment that many 
families may not be able to make due to other obligations (e.g., work, school) as well as the 
cost associated with lost work and travel expenses.
Because many families who need treatment are not receiving it, researchers and clinicians 
must initiate innovative strategies to make behavioral treatments for nonadherence more 
accessible. Use of technology, such as video conferencing, serves as one medium through 
which these barriers can be overcome. By delivering adherence interventions via 
teleconferencing, families are able to receive treatment directly from the comfort and 
privacy of their own home. Technologically-based means of communication play an integral 
role in the lives of adolescents. Using technology to deliver adherence interventions to youth 
across the country may result in the advent of more generalizable, cost-efficient, and 
acceptable treatments. This is the first known large scale multisite national RCT using 
telehealth to deliver a behavioral treatment specifically for nonadherence to treatment.
2. Objectives of the TEAM trial
The Telehealth Enhancement of Adherence to Medication (TEAM) trial is a multi-site 
randomized control clinical trial funded by the National Institute of Child Health and Human 
Development (NICHD) at the National Institutes of Health (NIH). TEAM will aim to 
overcome accessibility barriers by delivering a face-to-face multicomponent behavioral 
intervention via an online/telehealth format (i.e., Skype™). Building on our pilot work using 
telehealth technology29, the effect of a telehealth behavioral treatment (TBT) will be 
compared to an education only (EO) intervention among adolescents found to be 
nonadherent with traditional IBD treatment. We anticipate that participants in the TBT arm 
will demonstrate statistically significant improvements at post-treatment and 3-, 6-, and 12-
month follow-up compared to participants in the EO arm for both medication adherence and 
secondary outcomes (i.e., disease severity, patient quality of life, and health care utilization).
Many of the behavioral strategies used in addressing nonadherence in the TEAM Study can 
also be applied to other chronic illness populations. For example, “forgetting” is a common 
barrier reported across youth with chronic conditions. Interventions to address this barrier 
(e.g., improved organizational skills, reminder systems) can be readily applied across youth 
with different chronic conditions. Thus, although this study focuses specifically on a 
population known to be among the highest risk for nonadherence, strategies and lessons 




Participants will be recruited from seven pediatric hospitals. Approximately 305 participants 
will be enrolled in the study, with an estimated 194 randomized to receive either the TBT or 
EO intervention. Eligibility for randomization to treatment will depend on adherence data 
collected at the conclusion of a 4-week run-in period (see Figure 1 for an overview of study 
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design). Participants who complete the run-in phase with an adherence rate equal to or above 
90% (according to pill count) will be finished with study participation (total time 
commitment: 4 weeks). Those taking less than 90% of doses will continue on to 
randomization to either the TBT or EO intervention for a total time commitment of 15 
months (4 week run-in + baseline assessment + 2 month intervention + post-treatment, 3-, 6- 
and 12-month follow-up assessments). The 90% cut point, rather than 80%, was selected to 
provide a stricter test of the adherence intervention since there are no data to support 
therapeutic efficacy at 80% adherence for most medications including those of concern in 
this RCT. The study protocol was approved by the governing institutional review board at 
all seven study sites.
3.2 Inclusion Criteria
Adolescents between the ages of 11 and 18 years who have been diagnosed with IBD will be 
eligible for the study. Participants must be prescribed a daily oral immunomodulator (e.g., 6-
MP/azathioprine, methotrexate) and/or a 5-ASA (e.g., Pentasa, Asacol) in pill form so that 
adherence to medication can be electronically monitored. As caregiver and adolescent 
interaction is needed for the intervention portion of the study, the adolescent will be required 
to live at home. All participating adolescents must have at least one caregiver consistently 
completing study visits along with the adolescent. A secondary caregiver will also be 
allowed to participate in the Skype™ intervention sessions, provided informed consent is 
obtained prior to these sessions. Additionally, both the caregiver and adolescent must be 
fluent in English.
3.3 Exclusion Criteria
Families will be excluded from the study if the adolescent or caregiver has been diagnosed 
with a pervasive developmental disorder or a serious mental illness, such as schizophrenia or 
bipolar disorder. Medical chart reviews will be conducted by study personnel at each site to 
verify eligibility for the study.
3.4 Recruitment and retention
Recruitment will be conducted over the course of approximately 40 months at the seven 
participating pediatric hospitals: Cincinnati Children’s Hospital Medical Center (CCHMC), 
Connecticut Children’s Medical Center (CCMC), Children’s Hospital of Philadelphia 
(CHOP), Nationwide Children’s Hospital (NCH), Children’s Hospital of Pittsburgh (CHP), 
UCSF Benioff Children’s Hospital (UCSF), and Children’s Mercy Hospital (CMH). Such 
large scale collaboration between prominent pediatric institutions to address a critical 
clinical care issue represents a positive move toward improving children’s health on a 
national-level and is a significant improvement over single-site, regionally-bound research 
which has dominated pediatric behavioral intervention research. CCHMC will be the lead 
coordinating site, and each site will have a site-specific Principal Investigator (PI) and at 
least one study coordinator. Designated study personnel across all sites will be responsible 
for identifying eligible patients via medical chart review or direct physician referral.
Recruitment will occur via telephone or in person during the patient’s regularly scheduled 
gastroenterology clinic visit or infliximab infusion. For patients recruited via telephone, 
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coordinators at each study site will send recruitment letters which will give a brief 
explanation of the study, PI names, and a local opt out telephone number that families can 
call if they do not wish to be contacted. Two weeks after letters are sent, families that have 
not opted out of the study will be contacted and provided with an in-depth description of the 
TEAM trial. Families interested in participating will be mailed consent/assent forms to 
review over the telephone with their site coordinator. Completed forms will be returned to 
the site coordinator, who will then upload them to a secure website, along with family 
demographic information, for CCHMC coordinators to download and initiate participation. 
Referrals by gastroenterologists will be screened for eligibility based on previously specified 
study inclusion/exclusion criteria. If ineligible, the gastroenterologist will be notified so an 
appropriate referral can be made.
Once enrolled, participant progress will be monitored and managed by study staff at 
CCHMC. Compensation in the form of debit cards will be mailed to families immediately 
upon completion of each study visit, and rates will increase as families progress through the 
study to promote study retention. Adolescents and caregivers will each receive $20 for 
completing the baseline assessment, each of the four intervention sessions, and the post-
treatment assessment. Compensation for completing the 3-, 6-, and 12-month follow up 
visits will be $25, $30, and $35 per person, respectively. In addition, the study 
interventionist will maintain phone and email contact with families throughout the 
intervention, as outlined in the manualized treatment protocol, to promote study retention. 
This includes regularly scheduled contact outlined in the session manual as well as 
communication with families to reschedule any missed sessions.
3.5. Randomization
Participants will be randomized to treatment if: 1) they are less than 90% adherent to their 
prescribed oral medication during the 4-week run in, and 2) complete the online baseline 
assessment. Upon meeting these two criteria, a request containing the patient name and 
study site will be sent by the CCHMC study coordinator to the divisional data core, who will 
manage the randomization process. Overall randomization to TBT or EO will be 1:1. A 
stratified (by site) block randomization designed by the study’s biostatistician will be used, 
with each enrollment site’s randomization plan including randomly generated blocks of size 
2 and 4. The divisional data core will use this plan to randomize each patient to an 
intervention arm. They will report the treatment assignment condition to the lead 
interventionist, who oversees the intervention portion of the trial.
3.6. Blinding
All study investigators, coordinators, and treating gastroenterologists, including the PI, and 
those involved in the collection of outcomes data, will be blinded to treatment condition. 
Only the divisional data core and study interventionists will be aware of treatment 
assignment.
3.7. Assessment and outcome measures
Web-based assessments will occur at baseline, post-treatment, and 3-, 6-, and 12-month 
follow-up. Telephone interviews will also be conducted at each time point to gather pill 
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count information and obtain disease severity. Health care utilization data will be collected 
via medical chart review for 15 months prior to, and after, the date of enrollment.
Medication adherence
Electronic monitoring: Participants will be given a Medication Event Monitoring System 
(MEMS®) 6 Trackcap for each prescribed immunomodulator and/or 5-ASA. MEMS tracks 
adherence to medication by recording the time and date of bottle openings via a microchip 
embedded in the cap. Participants will use their MEMS bottles during the run in period and, 
if randomized, they will continue to use it throughout the entire 15 month enrollment period. 
Data will be downloaded from MEMS caps during regularly scheduled clinic visits at each 
enrollment site and exported to a computer for review and statistical analysis. Although the 
frequency of regularly scheduled clinic visits depends on a number of factors (e.g., patient 
health status, provider judgment), the microchip embedded within in each MEMS cap is 
capable of storing several years of data. Thus, if a patient misses a scheduled appointment, 
data will remain accessible in the future. The patient’s daily adherence percentage will be 
the primary outcome variable.
Pill count: Pill count data will also be collected for the monitored medication(s). 
Information collected will include dose, most recent refill date, quantity of refill, and 
number of pills remaining. Pill count data will be the primary adherence report during the 4-
week run in and will be used to determine eligibility for randomization (i.e., adherence rate 
less than 90%). This was chosen because remote MEMS data downloads are not available. 
Downloading of these data require in-person visits and most patient clinic visits will not 
coincide with the study randomization timeline. Thus, to minimize family burden, an 
alternative, reliable and objective method of assessing adherence (e.g., pill counts)30 was 
chosen to determine eligibility. Pill counts will be conducted by parents with study 
personnel via telephone. Pill count adherence rates will be calculated using the following 
formula: doses consumed ÷ doses prescribed × 100. Pill count data will be collected at all 
assessment time points and will serve as secondary adherence data in the unlikely event that 
MEMS data are not available due to equipment malfunction or participant loss of MEMS 
bottles.
Disease severity: Disease severity will be assessed via telephone interview at each 
assessment time point using either the Partial Harvey Bradshaw Index31 (PHBI; for patients 
with Crohn’s Disease) or Pediatric Ulcerative Colitis Activity Index32 (PUCAI; for patients 
with ulcerative colitis or indeterminate colitis). Questions vary by measure; however, items 
generally address abdominal pain, frequency and consistency of stools, limitation in activity, 
and overall well-being. The PUCAI assess patient symptoms within the last 2 days whereas 
the PHBI records symptomology within the past week. Higher scores on both measures 
denote more active disease. Both measures are well-validated and used reliably in IBD 
research (r=.81–.86 and r=.91 for PHBI and PUCAI respectively31–33).
Health care utilization: All health care utilization data will be collected by study staff; no 
data will be completed by participants. Medical charts will be reviewed by study staff at 
each enrollment site to determine health care utilization for the 15 month period prior to, and 
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directly following, enrollment. Chart review variables will include number of IBD-related 
hospital admissions, emergency department visits, gastroenterology outpatient visits, 
psychology visits, laboratory visits, infliximab infusions, telephone encounters, medication 
refill requests, surgeries, and other necessary referral services due to the IBD diagnosis (e.g., 
ophthalmology, urology).
Patient-reported health-related quality of life: The IMPACT-III questionnaire will be 
completed online by patients at each time point to assess patient health-related quality of life 
(HRQOL). This 35-item self-report of HRQOL asks patients to rate the extent he/she is 
affected by a particular IBD issue (e.g., stomach pain) on a 5-point Likert scale. Total scores 
range from 35 to 175 and higher scores denote a higher quality of life. The measure has 
demonstrated good reliability (α = .90, test-retest estimates = .9034) and validity in current 
research.
In addition to these outcome measures, patients and caregivers will also complete behavioral 
measures to assess psychosocial functioning, barriers to adherence, problem solving, and 
treatment responsibility. These measures will assess aspects of patient and family 
functioning that often correlate with medication nonadherence and may help identify 
mechanisms of change in the intervention employed in the TEAM trial.
Behavior Assessment System for Children-Second Edition, Parent Rating Scale 
(BASC-2-PRS)35: The BASC-2-PRS is a widely used inventory to assess and identify 
children and adolescents (ages 2–18; different forms for developmental levels) with 
emotional disturbances and behavioral disorders. The BASC measures externalizing, 
internalizing, and school problems, adaptive skills, and other problems. This measure has 
adequate internal consistency (.80 and .90 with adolescents) and test-retest reliability (.80’s 
to .90’s over a 1-month period).
Brief Symptom Inventory (BSI)36: This parent self-report measure consists of 53 items 
that assess psychological functioning and distress. Symptoms are categorized into 9 
symptom scales: Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, 
Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, and Psychoticism. Each 
item is rated on a 5-point rating scale with higher scores meaning higher symptom severity. 
Cronbach’s alpha37 reliability ranges from .71 to .8536.
Parent and Adolescent Medication Barriers Scale (PMBS and AMBS)38: This patient-
report (17-item) and caregiver-report (16-item) measure assesses perceived barriers to 
treatment adherence. Respondents rate the extent to which he/she is affected by each item 
(i.e., barrier) addressed. Both patient- and caregiver-report forms have demonstrated good 
reliability (α = .86 for patient, α = .87 for caregiver).
Social Problem-Solving Inventory-Revised Short (SPSI-RS)39: This parent and patient 
self-report is a 25-item measure assesses 5 different dimensions of social-problem solving: 
Positive Problem Orientation (PPO), Negative Problem Orientation (NPO), Rational 
Problem Solving (RPS), and Impulsivity/Carelessness Style (ICS), and Avoidance Style 
(AS). Greater problem solving ability is indicated by higher scores on the PPO and RPS and 
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lower scores on the NPO, AS, and ICS. The SPSI-R also generates an overall problem 
solving ability score, with higher scores indicating more adaptive problem solving abilities. 
The SPSI-RS has good reliability and validity39.
Allocation of Treatment Responsibility (ATR)40: The ATR is an 18-item assessment of 
treatment responsibility for patient- and caregiver-report. The measure has 3 subscales to 
assess responsibility for oral medication, clinic visits, and laboratory visits. The oral 
medication and clinic visits subscales will be used for this study. Respondents rate each 
question on a four-point Likert scale with a higher score denoting higher responsibility. Both 




Interventions in the TEAM trial will be delivered by post-doctoral fellows, psychology 
interns/residents, and master’s-level graduate students who have a background in child 
health/pediatric psychology and behavioral approaches to health promotion. All 
interventionists will undergo a structured training program which includes: 1) a broad 
overview of study aims and organization, 2) educational readings relevant to the study 
population and selected treatment approach (e.g., physiology and medical treatment of 
pediatric IBD, nonadherence in pediatric IBD, problem solving training), 3) orientation to 
the technology used in session and in data collection, 4) listening to complete audio session 
recordings for a prior TBT and EO participant, and 5) role playing the entire manualized 
TEAM intervention (TBT and EO) with the study’s lead interventionist serving as a mock 
participant. Mock sessions will place a heavy emphasis on understanding the medical 
management of IBD, psychosocial concerns of IBD in adolescence, and successfully 
applying the problem-solving approach to help families overcome barriers to adherence. All 
interventionists will be assigned both TBT and EO families across treatment sites and 
participate in weekly supervision with the lead interventionist to monitor participant 
progress, challenges in treatment, and to plan upcoming sessions. One interventionist will be 
assigned per family and all treatment sessions will be digitally recorded.
Each quarter, 20% of newly completed cases will be randomly selected for fidelity checks 
using trained coders who will be unaware of study aims and hypotheses. Fidelity checklists 
have been created for each treatment session and condition. In addition to documenting 
whether certain aspects of the protocol were delivered as planned, coders will be asked to 
document any potential cases of treatment cross-contamination (e.g., interventionist delivers 
an aspect of the TBT intervention to a family randomized to EO). Any deviation from the 
study protocol will result in remedial training of the interventionist.
4.2. Study sessions and use of Skype™
Participants will complete four study sessions, each approximately 2 weeks apart; a self-
guided session delivered via the study website (session 1) and three interventionist-lead 
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sessions delivered via Skype™ videoconferencing software (sessions 2–4). An overview of 
session content is provided in Table 1.
In session 1, IBD education, will be delivered to both TBT and EO families via the TEAM 
website. The educational materials on this website were designed by clinicians and patients 
at CCHMC to provide patients and families with IBD information that has been 
developmentally-tailored to adolescents. Topics covered include: 1) what is IBD?, 2) what 
are the symptoms of IBD and how is it diagnosed?, 3) how is IBD treated?, 4) what are 
potential complications of IBD?, 5) nutritional approaches to managing IBD, and 6) general 
management of IBD (e.g., at school, taking medicine, communicating with your doctor). 
Each section contains embedded links that provide additional information on the materials 
presented, videos of adolescent patients with IBD sharing their personal stories with regard 
to IBD (i.e., diagnosis, treatment, and day-to-day management), and a quiz to assess 
participant mastery of the material covered.
TEAM sessions 2–4 will be conducted via Skype™, a free video-conferencing software 
program. These sessions will be led by trained interventionists and contain treatment arm-
specific material. To facilitate telehealth sessions, families will be provided with a free 
webcam as well as instructions for downloading and using Skype™. A test trial of Skype™ 
will be conducted 1 week prior to the start of session 2 to familiarize families with the 
technology and troubleshoot any difficulties. For families in which use of Skype™ is not 
possible due to limited access to a computer or a reliable internet connection, sessions will 
be conducted over the telephone.
4.3. Telehealth Behavioral Treatment (TBT) Intervention
TBT sessions 2–4 will last approximately 60–90 minutes and will begin by reviewing the 
family’s most recent adherence behavior. While session content will vary slightly across 
sessions based on each family’s individual barriers to adherence (see Table 1), all TBT 
sessions will place a heavy emphasis on applying a structured problem solving approach41 
to overcome barriers to adherence. This approach is ideally suited to target nonadherence in 
this population as the majority of reasons for nonadherence to IBD treatment are behavioral 
in nature (i.e., forgetting). Other reasons for nonadherence (e.g., medication side-effects) 
will also be addressed as they occur and may involve helping the family problem-solve ways 
to overcome the barrier on their own or in collaboration with their medical team.
At the end of each TBT session, families will develop a behavioral contract which outlines: 
1) the barrier to adherence being targeted, 2) the family’s adherence goal, 3) the plan the 
family selected to overcome that barrier and reach their goal, 4) individual responsibilities to 
make this plan successful, and 5) the mutually agreed upon reward that the adolescent will 
receive if they reach their adherence goal (see Figure 2 for a sample). Families will be 
instructed to follow this contract for the next week and to track their level of success in 
implementing the plan and improving their adherence. Families will receive a telephone call 
from their interventionist approximately 1 week after their problem solving session. The 
purpose of this call is to check in on the family’s progress, provide reinforcement for their 
effort, and re-implement problem solving if the family has been unsuccessful in reaching 
their goal.
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4.4. Education Only (EO) Intervention
EO sessions will last approximately 20–30 minutes and will focus on providing education 
information regarding IBD management and relevant local and national resources for 
patients with IBD. Educational material will be customized to the patient’s current IBD 
regimen (session 2), geographic location (session 3), and current lifestyle habits (session 4). 
Families will receive an email from their interventionist approximately 1 week after their 
session which summarizes prior session content and provides them with additional web-
based resources relevant to the session content.
4.5. Data Safety Monitoring Board
A Data Safety Monitoring Board (DSMB) has been created to maintain safety and 
regulatory compliance across sites. The DSMB is comprised of three prominent experts in 
their respective fields and includes a pediatric psychologist, biostatistician, and 
gastroenterologist. Members of the DSMB will review study reports during biannual 
meetings with the PI and CCHMC study coordinators. Reports will include enrollment and 
randomization numbers per site, withdrawal rates, reasons for withdrawal, adverse events, 
and overall progress toward study objectives. No interim analyses will be conducted. 
Adverse events and protocol deviations will be promptly reported to CCHMC, reviewed by 
the PI, and reported to the IRB, if necessary.
5. Data Management & Analyses
5.1. Data Management
All data will be managed by the divisional data core at CCHMC. The data core is comprised 
of a database programmer, data manager, and application developer who will develop a 
study-specific website for data collection and patient education. Questionnaire data will be 
entered by patients and caregivers directly into the secured study website, and pill count and 
disease severity data will be entered manually by trained study staff at CCHMC. Data 
entered into the study website will be backed up nightly on a secure server. Chart reviews 
conducted by study coordinators at other sites will be transferred to CCHMC via secure 
server. Study staff at CCHMC will review data and utilize a double entry system to ensure 
accuracy of data. At minimum, the data core will run monthly quality reports to maintain 
reliability across all databases.
5.2. Power Analyses and Sample Size Considerations
Sample size calculation was based on our prior RCT studies using the proposed behavioral 
intervention to improve treatment adherence in pediatric IBD, in which we have observed a 
25% increase in medication adherence and medium effect sizes (d = 0.57). We anticipate a 
modest (i.e., 5%) increase in adherence for patients in the EO condition due to education and 
attention intervention. A total of 194 children will be needed for this study (97 children/arm 
× 2 arms). This sample size estimate is predicated upon a two-group repeated measures 
analysis of variance test with five observation periods, a difference in adherence of 20% 
attributable to TBT at the 12-month evaluation (effect size = 2.33 OR), R = 0.70 
(autocorrelation), and 90% power (α = 0.05). Although the study is sufficiently powered at 
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77 children/arm, this estimate allows for a very liberal 20% attrition rate (97 × 0.80 = 77.6 
children/arm) across the 12-month study period.
5.3. Data Analytic Plan
Missing Data—Patterns of missingness will be evaluated for outcomes as well as 
covariates, for the group as a whole as well as each treatment group, individually, in an 
effort to uncover any patterns among the data. Imputation procedures will be handled in 
accord with recommendations outlined in Little and Rubin42. The linear mixed effects 
models described below are quite capable of accommodating unbalanced designs.
Preliminary Data Analyses—Descriptive statistics will be computed for all relevant 
variables in the data set, including measures of central tendency, variability, and association, 
where appropriate. Preliminary analyses will include evaluating the distributional properties 
of key outcomes overall, by adherence to medication type, by interventionist, and by 
observation period using graphical and numeric methods. In the event that the primary 
outcome, adherence rate, deviates substantially from normality and linear mixed effects 
models are deemed less appropriate, alternative transformational and modeling strategies 
will be considered.
Hypotheses Testing—Primary Aim analyses will consist of a regression-based 2-factor 
repeated measures analysis, considering post treatment, 3-, 6-, and 12-month monitoring as a 
nested effect. The primary outcome will be the electronically monitored adherence rate. Our 
testable covariate will be treatment arm (TBT, EO). A baseline measure of adherence will be 
included in the model as an influential covariate while a limited number of behavioral 
measures will be included as potential covariates (i.e., BASC parent- and self-report, BSI). 
A linear mixed-effects model is deemed most appropriate given its ability to handle repeated 
(daily) observations over a 12-month period within the context of unbalanced data structures 
while allowing for alternative time-series covariance structures. Significant differences 
between treatment arms will be evaluated at the nominal α = 0.05 level, immediately 
following initial treatment, and at the 3-, 6-, and 12-month follow-up evaluations 
specifically to examine stability of treatment effects over time. Sphericity will be evaluated 
as appropriate; residuals will be evaluated for normality, constant error variance, and 
independence. Semiparametric regression in the context of the previously described mixed 
model framework will also be considered should assumptions for the parametric model not 
be met. Once data are collected, appropriate basis functions will be chosen for analysis. The 
linearity assumption will be tested using a likelihood ratio test.
Secondary Aims hypotheses will be modeled and analyzed similarly to the Primary Aim; 
however, the outcomes of interest will vary by hypothesis: disease severity (H2), HRQOL 
(H3), and health care utilization (H4). The testable covariate in each case will be treatment 
arm (TBT, EO), after adjusting for significant behavioral covariates (i.e., BASC parent- and 
self-report and BSI). As with the Primary Aim, we will test the difference between arms at 
post-treatment and 3-, 6-, and 12-month follow up (α < 0.05). Difference in health care 
utilization between conditions at post-treatment is not expected due to the brief time span 
between baseline and post-treatment; thus, differences between groups on health care 
Hommel et al. Page 11













utilization will be examined only at 3-, 6-, and 12-month follow up. Within the context of 
these secondary analyses, selected mediators (patient/parent functioning, barriers to 
treatment, enhanced problem solving) will be included in the aforementioned Aim 2 models 
consistent with strategies outlined by Kraemer and colleagues43,44, Holmbeck45, and Baron 
and Kenny46. Specifically, analyses will be conducted using both direct and indirect effects 
with and without interaction terms involving the mediator and treatment variables to identify 
candidate mechanisms of influence.
6. Discussion
The TEAM trial is a multi-site randomized control clinical trial examining the efficacy of a 
multicomponent behavioral adherence intervention delivered via telehealth. Demonstrating 
the efficacy of telehealth approaches to treatment of nonadherence in pediatric conditions 
will be a critical step in overcoming accessibility barriers and reaching underserved 
populations. If evidence for efficacy is found, TEAM will give nonadherent patients, who 
would otherwise not receive behavioral treatment, the opportunity to learn and develop skills 
critical to effective daily medication management. Improved adherence may prevent future 
declines in psychosocial and medical functioning currently associated with nonadherence. 
This in turn, may improve patient quality of life and reduce health care expenditures and 
burden on the health care system. Indeed, we recently published a review demonstrating 
increased health care utilization among pediatric patients who were nonadherent to their 
medication regimen47.
Findings from the TEAM trial will have implications for both clinical practice and research. 
For this trial, we are using a web-based video conferencing service that is readily available 
and highly utilized by the general public; however, it is not HIPAA compliant, which may 
limit the extension of this exact protocol into practice or other research settings. Researchers 
interested in using video conferencing as a method of treatment delivery may want to 
consider using HIPAA compliant services, such as Citrix GoToMeeting, SecureVideo, or 
Secure Telehealth. Although such services provide greater protection and security, each 
would require patients and families to receive specific training on their use since they are not 
commonly used applications. This may require additional time and investment on the part of 
researchers and families. In addition, licensure across state lines and reimbursement for 
professional services remain as barriers to implementing telehealth services on a large scale 
currently. Nevertheless, many opportunities are available to treat patients with self-
management difficulties within state lines, though they may have to be physically located at 
another clinical office (e.g., a colleague’s office) in order to secure reimbursement. 
Partnerships with multidisciplinary practices and hospitals will be critical to disseminating 
the application of telehealth approaches to treating nonadherence in the near future. As 
reimbursement practices continue to evolve in the next few years it will be important to have 
evidence from RCTs like the TEAM trial to provide an empirical base from which to argue 
for better reimbursement for telehealth services. This is also likely to be an economical 
approach to care as intervention personnel would not be needed locally as the intervention 
could be delivered from various locations to wherever it is needed.
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With regard to research, the TEAM trial will inform the field on the potential of telehealth 
approaches to treating pediatric behavioral health problems. We will collect data on the use 
of the online education module with regard to time spent on the module, frequency of 
accessing the module, and topics covered. We will also learn and be able to share a 
considerable amount of information regarding the logistical aspects of this multisite trial that 
spans all time zones in the United States. Practical issues such as how to provide treatment 
from the east coast to the west coast at a convenient time for patients/families and how to 
quickly build rapport using virtual face-to-face interaction will be very informative to 
ongoing telehealth treatment outcome research efforts. Finally, our secondary outcomes 
assessment will allow us to better understand the impact of telehealth-delivered behavioral 
intervention to improve disease status, HRQOL, and health care utilization. A significant 
effect on any of those would represent the potential to have a substantial financial impact on 
health care as each of these outcomes is related to increased costs.
The TEAM trial faces several anticipated challenges. Each site has its own unique research 
infrastructure and resource needs, which helps determine how recruitment is handled. We 
are able to recruit patients at other study sites via telephone from the primary site in most 
cases, but this involves some challenges. First, after initial screening and contact from their 
local facility, patients and families receive a call from someone in a different city or state. 
Although they are prompted that this will happen, it’s often difficult to keep that in mind, so 
families may require some reminding about why they are receiving the call. Calls are also 
sometimes ignored due to unfamiliar phone numbers on caller ID. In addition, each site has 
multiple ongoing studies, which necessitates careful consideration of how each one impacts 
the others in terms of recruitment and potential impact on outcomes. Referrals from 
clinicians to the TEAM study are an attractive option since the resources to address 
nonadherence are not readily available at each site; however, this requires frequent 
communication to clinicians that referrals are an option for their patients.
Because patients and families are accustomed to in-person contact with clinicians, the lack 
thereof may impact participant recruitment and retention. In addition, the targeted patients 
we are recruiting for this trial are normally nonadherent, not only to treatment regimens, but 
often to medical appointments as well. While we have attempted to preemptively address 
this issue, the convenience of completing treatment sessions online from home may connote 
to patients a loosening of expectations for treatment session attendance.
As with any RCT, participants could potentially be dissatisfied with the random assignment 
to treatment arm they receive. Related to this is an issue that is specific to adherence trials. 
Some participants may simply not accept the findings from the run-in period. Many families 
believe they are significantly more adherent than objective data reveal. This is true for 
everyone’s estimates of their own health promoting behavior, not just patients. Due to this 
perception bias, some families are likely to not agree with the results of their run-in data, 
which will result in a subset of patients who are eligible for treatment not being randomized.
An overarching theme of the TEAM trial is to provide treatment to those who need it in a 
convenient manner. Convenience is addressed via the telehealth approach as well as having 
a focused and time-limited intervention consisting of four substantive sessions. Several 
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issues may arise in a large trial with a treatment approach like this. First, the treatment might 
not be long enough/contain enough contacts to result in long-term acquisition of behavioral 
skills that result in better medication adherence. Second, the intervals between treatment 
sessions may not be long enough. That is, there may be enough sessions, but more time may 
be needed for skill acquisition. Finally, some families might experience significant 
psychosocial distress, such as depression, anxiety, divorce, economic hardship, etc., which 
may impact the extent to which patients are adherent to their medication regimens. 
However, these issues are not addressed in the TEAM trial’s intervention manual. We strove 
to have a focused treatment approach targeting nonadherence. While this is advantageous in 
targeting a specific set of behavioral factors, it is limited by not addressing the wide array of 
factors that may impact adherence.
7. Conclusions
Randomized controlled trials examining the efficacy of treatment for medication 
nonadherence in pediatric populations are rare despite the impact of nonadherence on 
patients and health care costs and the importance of building behavioral skills that promote 
optimal health in this developmental period. It is anticipated that improvements in adherence 
to medication regimens will result in improved overall health, better health-related quality of 
life, and decreased health care utilization. Further, improvement in self-management of 
adolescent patients is optimal because this age group is at a critical developmental period in 
which long-term health behavior habits are formed.
Use of innovative methods of care delivery in this trial should be both appealing to the target 
population (i.e., adolescents) and convenient for families, which is a significant barrier to 
receiving this type of treatment. Moreover, the benefit of using a telehealth approach is that 
geographical limitations are quite minimal. Indeed, the sites involved in this trial span the 
continental United States. If demonstrated to be efficacious, the TEAM intervention could 
theoretically be delivered across international borders.
Going forward, the existing policies pertaining to licensure reciprocity and reimbursement 
must be revisited as the development and application of technology in health care is 
advancing at a faster rate than health care insurance and law. Better use of existing 
resources, on-site or available virtually, will result in decreased health care costs and better 
comprehensive and preventive care that incorporates behavioral health skill training. With 
health care organizations beginning to be incentivized based on the health care outcomes of 
their patients (e.g., decreased readmission rates), improved behavioral health care that 
results in better disease management will be increasingly important.
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Overview of TEAM Study design
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Sample Adherence Contract following a TBT session
Hommel et al. Page 19

























Hommel et al. Page 20
Table 1
Overview of Telehealth Behavioral Treatment (TBT) and Education Only (EO) session content
Week TBT EO
6 Session 1: IBD education delivered via TEAM website
7 Skype™ technology testing Skype™ technology testing
8 Session 2: Parental monitoring of adherence, introduction to 
adherence monitoring, use of problem solving approach to 
overcome barriers to adherence
Session 2: Review of adolescent’s specific medication regimen. 
Tailored discussion of medication regimen including mechanism of 
action within the body and potential side effects
9 Telephone check in of family’s progress Follow-up email of previous session materials and links to related 
educational materials
10 Session 3: Functional analysis of family’s specific barriers to 
adherence, discussion of organizational tools to improve 
adherence, problem solving of one adherence barrier
Session 3: Discussion of local and national resources available to 
patients with IBD via the Crohn’s and Colitis Foundation of 
America
11 Telephone check in of family’s progress Follow-up email of previous session materials and links to related 
educational materials
12 Session 4: Transition of IBD treatment responsibility from the 
parent to the adolescent, maintenance of adherence gains, 
problem solving one future barrier to adherence
Session 4: Education on the role of healthy lifestyle habits (i.e., 
nutrition, hydration, sleep, and exercise) as part of a comprehensive 
IBD management approach
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